SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association For Continuing Education

Course Director
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Kevin Flaherty, MD, MS
Professor in Pulmonary and Critical Care Medicine
University of Michigan Health System
Ann Arbor, MI

Franck Rahaghi, MD, MHS, FCCP 
Chairman, Department of Pulmonary Medicine
Head, Pulmonary Education and Rehabilitation 
Cleveland Clinic Florida
Weston, FL

Jan Basile, MD
Professor of Medicine
Seinsheimer Cardiovascular Health Program
Division of General Internal Medicine
Medical University of South Carolina
Ralph H. Johnson VA Medical Center
Charleston, SC

: Idiopathic Pulmonary Fibrosis: Making Sense of Diagnostic and Therapeutic Options in Primary Care
Activity/Course #:
: NCME330x

: Free
Release/Start Date:
: Apr 21 2017
Expiration Date:
: Apr 20 2018
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 0
Hardware/Software Requirements:
Welcome to the National Association for Continuing Education webcast from the NACE Conversations in Primary Care 2017 conference. 

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia. It is the most common and lethal type of idiopathic interstitial pneumonia, and is a devastating disease associated with irreversible destruction of the lung. IPF is associated with increased comorbidity, healthcare resource utilization, and direct medical costs. The disease has a poorer prognosis than other interstitial lung diseases, with a median survival of 3 years from diagnosis. Unfortunately, the recognition and management of IPF remains suboptimal in clinical practice with confusion regarding the availability of various treatment options for IPF.

This webcast presents the diagnostic and therapeutic strategies available to help primary care clinicians not only recognize this lethal disease at an early stage, but also effectively assist in the care of these patients after diagnosis.

The program format utilizes an interview style format incorporating a moderator, Dr. Jan Basile, and faculty thought leader, Dr. Kevin Flaherty. The program incorporates case based vignettes, didactic presentations, and an interactive discussion with audience participation to deliver information while increasing practitioner skills and confidence in patient evaluation and management. This webcast was recorded live and is being used with the permission of the presenters.

Learning Objective(s):

After completing this program participants should be able to:

  1. Implement an appropriate strategy for diagnosing a patient with idiopathic pulmonary fibrosis.
  2. Discuss and contrast the available pharmacotherapeutic options for patients with IPF.
  3. Describe the non-pharmacotherapeutic options for IPF patients.
  4. Establish the clear role for the primary care clinician in diagnosing and managing disease in IPF patients.

How To Obtain Your CME Certificate

         1. Register for the course at
         2. View the content.
         3. Complete and submit the post-test and evaluation.
         4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME
         5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Kevin Flaherty, MD, MS serves as a consultant for Boehringer Ingleheim and Genentech. Dr. Flaherty also serves on the advisory board for Fibrogen.

Franck Rahaghi, MD, MHS, FCCP serves as a consultant/speaker/researcher for Boehringer Ingleheim. Dr. Rahaghi also serves as a researcher for Merck.

Jan Basile, MD serves as on the speakers bureau for Amgen, Arbor, and Janssen. Dr. Basile also serves as a consultant for Novartis. Additionally, Dr. Basile serves as a researcher for Medtronic and on the writing committee for Up-to-date.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.

Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.